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INTRODUCTION
The wide use of heparin led to the increasing recognition of
untoward complications including heparin-induced throm-
bocytopenia/thrombosis. This phenomenon, which is charac-
terized by a sharp drop in the platelet count and subsequent
platelet activation and aggregation after heparin treatment (1,
2), is caused by the binding of heparin-IgG immune complex-
es to platelets by the Fc portion of the IgG molecule, and the
binding of antibodies to platelets is markedly enhanced by the
presence of heparin (3, 4).
Since heparin is an anticoagulant most often used during
hemodialysis and patients with end-stage renal disease on main-
tenance hemodialysis are repeatedly exposed to heparin, one
might expect a higher frequency of heparin-dependent anti-
bodies in hemodialysis patients. Since these antibodies are asso-
ciated with thromboses (5) and thrombotic complications such
as vascular access obstructions are common in patients on main-
tenance hemodialysis, one might also expect the association
between heparin-dependent antibodies and vascular access
obstructions in hemodialysis patients. However, the incidence
of anti-heparin-platelet factor 4 antibodies and the association
between anti-heparin-platelet factor 4 antibodies and vascu-
lar access obstructions in hemodialysis patients are not well
known so far.
The purpose of this study was to determine the prevalence
of anti-heparin-platelet factor 4 antibodies and to evaluate the
risk of vascular access obstruction imposed by these antibodies
in patients on maintenance hemodialysis.
MATERIALS AND METHODS
A total of 91 end-stage renal disease patients on maintenance
hemodialysis (41 men, 50 women, mean age 51.0±13.1 yr)
and 40 healthy subjects (20 men, 20 women, mean age 47.9
±13.5 yr) were included in this study. We excluded patients
who had never used heparin during hemodialysis for various
medical reasons. Blood samples were obtained prior to the he-
modialysis procedure. Informed consent was obtained from
each subject.
All end-stage renal disease patients were undergoing reg-
ular hemodialysis 8 to 12 hr weekly using a cellulose acetate
hollow-fiber dialyser (surface area 1.2 m2, Gambro, Stockholm,
Sweden) at a hemodialysis unit of the Soonchunhyang Uni-
versity Chonan Hospital, Chonan, Korea.
The anti-heparin-platelet factor 4 antibodies were measured
by enzyme immunoassay according to the instructions of the
manufacturer (Asserachrom HPIA, Diagnostica Stago, Paris,
France). The microtiter plate was covered by heparin-platelet
factor 4 complexes. Bound antibodies were discovered through
a mixture of anti-human IgG, IgA, and IgM. Absorbance was
measured at 492 nm, and the cut-off was defined as mean+
2S.D. The lower limit was confirmed in our laboratory by test-
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Anti-Heparin-Platelet Factor 4 Antibody is a Risk Factor for Vascular
Access Obstruction in Patients Undergoing Hemodialysis
Since heparin is an anticoagulant commonly used in hemodialysis and the patients
on hemodialysis are repeatedly exposed to heparin, heparin may be the cause of
the development of heparin-dependent antibodies and thrombotic complications in
patients on hemodialysis. The purpose of this study was to determine the prevalence
and the clinical significance of the antibodies against heparin-platelet factor 4 com-
plexes as determined by enzyme immunoassay in patients on maintenance hemodial-
ysis. The prevalence of anti-heparin-platelet factor 4 antibodies was higher in hemo-
dialysis patients than in normal subjects (8.8 vs 0.0%, p<0.05). The number of past
episodes of vascular access obstruction per year was significantly higher in the  anti-
heparin-platelet factor 4 antibody positive group than antibody negative group. Anti-
heparin-platelet factor 4 antibody positive patients experienced more frequent vas-
cular access obstructions than control subjects. In conclusion, anti-heparin-platelet
factor 4 antibody might be a risk factor for vascular access obstructions in patients
with end-stage renal disease on maintenance hemodialysis.
Key Words : Anti-Heparin-Platelet Factor 4 Antibody; Renal Dialysis; Vascular Access Obstruction;
Kidney Failure, Chronic
Received : 13 May 2002
Accepted : 8 November 200270 E.-Y. Lee, K.-Y. Hwang, J.-O. Yang, et al.
ing 20 normal control serum samples. Plasminogen activator
inhibitor-1 (Asserachrom PAI-1, Diagnostica Stago, Paris, Fr-
ance) and tissue plasminogen activator (Asserachrom tPA, Di-
agnostica Stago, Paris, France) were also determined quanti-
tatively by enzyme-linked immunosorbent assay (6, 7).
Data were presented as mean±S.D. for continuous variables
and as frequency (%) for categorical variables. p-value was cal-
culated by Student’ s t-test for continuous variables or by Fish-
er’ s exact test for categorical variables. A value of p<0.05 was
considered statistically significant and all statistical analysis
was performed using SPSS for Windows (version 10.0, Chica-
go, Illinois, U.S.A.).
RESULTS
In 91 end-stage renal failure patients, the mean duration of
hemodialysis was 4.1±3.4 (range; 0.4 to 15.2) yr. The caus-
es of renal failure were diabetes mellitus (n=30), hypertension
(n=26), polycystic kidney disease (n=4), chronic glomerulo-
nephritis (n=13), and unknown (n=18). Normalized protein
catabolic rate was 1.1±0.3. Mean systolic and diastolic blood
pressures were 141.1±17.3 and 85.3±10.7 mmHg, respec-
tively. Seventy-six patients (83.5%) were on hypertensive med-
ications. The serum albumin level was 37±4 g/L and hema-
tocrit was 0.26±0.03. Serum calcium and phosphorus were
2.3±0.3 mmol/L and 1.6±0.6 mmol/L, respectively. Twenty-
six patients (28.6%) had experienced vascular access obstruc-
tion at least once. All of the patients had the arteriovenous fis-
tulaexcept only one patient who had the atreriovenous graft.
Eight patients were positive for anti-heparin-platelet factor
4 antibodies. The prevalence of anti-heparin-platelet factor 4
antibodies was higher in hemodialysis patients than in normal
subjects (8.8 vs 0.0%, p<0.05). The mean age was 50.6±7.2
yr, and the mean duration of hemodialysis was 63.3±55.8
months. Four patients experienced vascular access obstruction
more than once. None of them experienced a significant de-
cline of their platelet count after the initiation of heparin expo-
sure during hemodialysis treatment. Three patients also had
liver cirrhosis (Hepatitis B-associated in two patients and alco-
holic in one patient). The mean levels of plasminogen activa-
tor inhibitor-1 and tissue plasminogen activator were 18.06
±8.48 and 1.67±0.58 ng/mL, respectively, in patients posi-
tive for anti-heparin-platelet factor 4 antibodies.
The number of past episodes of vascular access obstruction
per year was significantly higher in the anti-heparin-platelet
factor 4 antibody positive group than in antibody negative
group (Table 1, p<0.05). There were no other significant dif-
ferences in age, sex, duration of hemodialysis, prevalence of
patients with a past history of vascular access obstruction, sys-
tolic and diastolic blood pressures, platelet count at the last
follow-up, hematocrit, calcium, phosphorus, plasminogen acti-
vator inhibitor-1, or tissue plasminogen activator levels be-
tween anti-heparin-platelet factor 4 antibody positive and
negative groups of hemodialysis patients (Table 1). There was
no significant difference in Kt/V, normalized protein catabol-
ic rate, mean dose of heparin used, or past history of cerebrovas-
cular accident between anti-heparin-platelet factor 4 antibody
positive and negative groups.
DISCUSSION
This study demonstrates that anti-heparin-platelet factor
4 antibodies were more prevalent in end-stage renal disease
patients who had been using heparin for prolonged periods
than in the control subjects. Anti-heparin-platelet factor 4
antibody positive patients experienced more frequent vascular
access obstructions than antibody negative patients. Therefore,
anti-heparin-platelet factor 4 antibody may be a risk factor for
vascular access obstructions in patients undergoing hemodial-
ysis.
The incidence of anti-heparin-platelet factor 4 antibodies
induced by heparin in patients with normal renal function
varied from 2.7% to 34% in various clinical settings (8, 9).
Because heparin is used in almost all hemodialysis patients, the
prevalence of these heparin-dependent antibodies might be
higher in patients on hemodialysis than in the general pop-
ulation who have never used heparin. Our study showed that
there was a higher prevalence of anti-heparin-platelet factor
4 antibodies in hemodialysis patients and this supports that
heparin can induce formation of these heparin-dependent anti-
bodies. The frequency of anti-heparin-platelet factor 4 anti-
body formation increased progressively with the duration of
heparin treatment (9). Recent reports have shown that during
prolonged heparin treatment 30-60% of patients with nor-
HD, hemodialysis; VAO, vascular access obstruction; BP, blood pres-
sure; PAI-1, plasminogen activator inhibitor-1; t-PA, tissue plasminogen
activator. Data were presented as mean±S.D. for continuous variables
and as frequency (%) for categorical variables.
Variable
Positive
(n=8)
Negative
(n=83)
p-value
Age (yr) 50.6±7.2 51.0±13.5 0.94
Male (%) 25.0 47.0 0.23
Duration of HD (yr) 5.4±4.7 4.1±3.3 0.30
No. with a past history of VAO (%) 50.0 26.5 0.16
No. of episodes of VAO (/yr) 0.49±1.19 0.13±0.30 0.03
Systolic BP (mmHg) 142.5±27.6 144.3±16.3 0.79
Diastolic BP (mmHg) 80.0±10.7 85.9±10.7 0.14
Platelet final (x10
9/L) 186.9±78.0 193.4±73.2 0.83
Hematocrit 0.27±0.05 0.26±0.03 0.72
Calcium (mmol/L) 2.4±0.3 2.3±0.2 0.77
Phosphorus (mmol/L) 1.5±0.6 1.6±0.6 0.53
PAI-1 (ng/mL) 18.1±8.5 15.1±5.4 0.17
t-PA (ng/mL) 1.67±0.58 1.55±2.58 0.90
Table 1. Comparisons between anti-heparin-PF4 antibodies
positive and negative groups of patients with end-stage renal
failure on maintenance hemodialysisHeparin Antibodies in Patients Undergoing Hemodialysis 71
mal renal function form anti-heparin-platelet factor 4 antibod-
ies after open heart surgery or vascular surgery (9, 10). Since
heparin is also used for a prolonged duration in maintenance
hemodialysis patients, the prevalence of these heparin-depen-
dent antibodies might be higher in patients on hemodialysis
than in patients on a short term heparin treatment. Surpris-
ingly, however, a longer duration of heparin treatment did not
lead to as high a percentage of anti-heparin-platelet factor 4
antibodies in chronic hemodialysis patients as expected. These
results might be caused by uremia-related obtundation of the
immune response in patients with end-stage renal failure. How-
ever, this hypothesis was not fully confirmed in this study.
Other studies have shown that vascular access obstruction
contributes substantially to the morbidity, mortality, and high
costs associated with hemodialysis treatment (11). Several risk
factors of vascular access obstruction including diabetes mel-
litus, hypotension, hypoalbuminemia, anticardiolipin antibod-
ies, increased serum levels of lipoprotein (a), and fibronectin
have been reported (11, 12), however, a significant percentage
of vascular access obstruction remains unexplained. A hyper-
coagulable state caused by alterations of coagulation and fibro-
lytic factors frequently occurs in renal failure (13). Anticoag-
ulation with heparin is intended to reduce these complications
during the hemodialysis procedure. However, paradoxically,
the administration of heparin can lead to heparin-induced
thromboembolic complications caused by the formation of
anti-heparin-platelet factor 4 antibodies (14), therefore, hep-
arin use in chronic dialysis patients might be a risk factor caus-
ing vascular access obstruction. Since the anti-heparin-platelet
factor antibody increases the number of past episodes of vas-
cular access obstruction in this study, we might say that hep-
arin dependent anti-heparin-platelet factor 4 antibody is a risk
factor for vascular access obstructions in patients receiving reg-
ular hemodialysis.
How antibodies can be generated and why only part of them
are pathogenic are not yet clear. However, the presence of the
IgG isotype at a high concentration and the clinical context
which induces accumulation and activation of platelets at
pathological sites, are suggested to be important factors for dis-
ease occurrence (15).
Several methods to detect the heparin-dependent antibodies
have evolved. The most recent tests for heparin-dependent
antibodies are based on the recognition that the antibodies are
directed against the heparin-platelet factor 4 complex by
enzyme immunoassay (3, 16). Since this method was more
sensitive and easier to perform than conventional platelet
function assays such as platelet aggregation, serotonin release,
and flow cytometry (17), and immunoassays and functional
assays agree in about 80% of cases (18), we applied the
method to determine the anti-heparin-platelet factor 4 anti-
bodies in this study. These antibodies, however, are generat-
ed only in part of heparin-treated patients, and still only a
subgroup of them develop vascular access obstruction.
In conclusion, the prevalence of anti-heparin-platelet factor
4 antibodies was higher in patients who had used heparin as
an anticoagulant during hemodialysis than a control subjects
and the number of past episodes of vascular access obstruction
was significantly higher in the anti-heparin-platelet factor 4
antibody positive patient group than in the antibody negative
patient group. Therefore, we suggest that the anti-heparin-
platelet factor 4 antibody is a risk factor for vascular access
obstructions in patients with end-stage renal disease on main-
tenance hemodialysis.
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